

The American Journal of Human Genetics, Volume 95

Supplemental Data

Partitioning Heritability of Regulatory and Cell-Type-Specific Variants across 11 Common Diseases

Alexander Gusev, S. Hong Lee, Gosia Trynka, Hilary Finucane, Bjarni J. Vilhjálmsson,
Han Xu, Chongzhi Zang, Stephan Ripke, Brendan Bulik-Sullivan, Eli Stahl,

Schizophrenia Working Group of the Psychiatric Genomics Consortium, SWE-SCZ

Consortium, Anna K. Kähler, Christina M. Hultman, Shaun M. Purcell, Steven A.

McCarroll, Mark Daly, Bogdan Pasaniuc, Patrick F. Sullivan Benjamin M. Neale, Naomi

R. Wray, Soumya Raychaudhuri, and Alkes L. Price

Supplemental Figures




Figure S1. Principal components analysis of WTCCC samples. Two most significant principal components are plotted for each disease cohort, with cases and controls color coded red and black respectively. Each sub-panel label specifies the variance in phenotype explained by all 20PCs in parentheses. MS and SP cohorts are known to be highly structured due to environment and ascertainment.




Figure S2. Principal components analysis of Swedish samples. Two main principal components are shown for analysis of GWAS data from the full Swedish Schizophrenia cohort. Homogenous Swedish samples are highlighted in blue.




Figure S3. Observed variance-component enrichment from simulated null architecture. Distribution of enrichment estimate over 1000 simulations with three different disease architectures performed in genotyped SNPs (top) and imputed SNPs (bottom). All phenotypes simulated without category-specific enrichment, red line showing expected enrichment of $1.0\times$. Red asterisk indicates significant difference from expectation (by z-test, accounting for 36 comparisons).




Figure S4. Enrichment of summary statistics under the null. Results for MAF-independent (left) and low-frequency (right) architectures shown for stratified QQ-plots (top) and P -value enrichment plots (bottom).




Figure S5. Partitioning of h_g^2 with imputed SNPs and MAF-independent causals. Estimate of h_g^2 from imputed SNPs in each functional category for phenotypes simulated from imputed SNPs with any frequency. Each section of the figure describes results from 200 simulations where all h_g^2 was induced in the titular functional category (highlighted in blue).




Figure S6. Observed P -value enrichment from simulated enrichment (MAF-independent).




Figure S7. Observed P -value enrichment from simulated enrichment (low-frequency).




Figure S8. Partitioning of h_g^2 with imputed SNPs and low-frequency causals. Estimate of h_{ig}^2 from imputed SNPs in each functional category for phenotypes simulated from imputed SNPs with MAF < 0.05 . Each section of the figure describes results from 200 simulations where all h_g^2 was induced in the titular functional category (highlighted in blue).




Figure S9. Partitioning of h_{g}^2 simulated in MAF-independent imputed data. Estimate of h_{g}^2 from genotyped SNPs in each functional category for phenotypes simulated from imputed SNPs from any MAF. Each section of the figure describes average results from simulations where all h_{g}^2 was induced in the titular functional category (highlighted in blue). Estimate h_{g}^2 is spread across multiple functional categories due to incomplete tagging. Error-bars indicate standard error from 200 simulations.




Figure S10. Partitioning of h_{g}^2 simulated in low-frequency imputed data. Estimate of h_{g}^2 from genotyped SNPs in each functional category for phenotypes simulated from imputed SNPs with $\text{MAF} < 0.05$. Each section of the figure describes average results from simulations where all h_{g}^2 was induced in the titular functional category (highlighted in blue). Estimate h_{g}^2 is spread across multiple functional categories due to incomplete tagging. Error-bars indicate standard error from 200 simulations.




Figure S11. Partitioning of h_g^2 from causal variants at the DHS boundary. Causal variants were sampled from non-DHS intronic and intergenic regions within 0-500bp (left, 29% of imputed SNPs) and 500-1,000bp (right, 15% of imputed SNPs) of any DHS region boundary. Box-plots shown % h_g^2 estimates over 200 simulations with MAF-independent causal variants. Phenotypes and GRMs from genotyped SNPs (top) and from imputed SNPs (bottom).




Figure S12. Individual trait analysis of coding and DHS variants. Forest plot of % h^2_g inferred for each trait over coding SNPs (top) and DHS SNPs (bottom). Total h^2_g shown for each trait and SNP platform in second column.




Figure S13. Functional enrichment of SNP-heritability in DHS regions. The ratio of observed % heritability over corresponding % of SNPs is reported as meta-analysis over all traits for four locus types. Light blue bars detail analysis of typed SNPs and dark blue bars detail analysis of typed and 1,000 Genomes imputed SNPs. “Known Loci” categories correspond to analysis restricted to 1MB regions around published genome-wide significant loci for the corresponding trait. We note that the choice of region size may impact the absolute enrichment, with larger regions expected to appear more like the genome-wide enrichment and yield a conservative estimate of the difference. This region size is expected to yield a representative estimate¹. SP, HT, and BD had too few known loci or could not converge in the local analyses and were excluded from all computations, resulting in slightly different overall values from Figure 1. Error bars define 95% confidence interval after adjusting for shared controls.




Figure S14. P-value enrichment in 11 traits. Fold-enrichment of P -values meeting a given significance threshold in each functional category. Enrichment plotted for all thresholds that contain at least 100 SNPs. Average over 11 traits shown in top-left for thresholds observed in all traits, with shaded region corresponding to standard error.




Figure S15. *P*-value enrichment in PGC2. Fold-enrichment of *P*-values meeting a given significance threshold in each functional category.




Figure S16. Power to detect significant h_g^2 enrichment. Phenotypes were simulated with DHS and coding enrichment matching the observed meta-analysis values in a 33,000 sample cohort. Power was then inferred as the fraction of 100 simulations where enrichment was significant at $P < 0.05$ over increasing sample sizes.




Figure S17. Heritability estimates in simulation with normalized allelic effect-sizes. Distribution of h_g^2 inferred by four variance-component models is shown over a range of disease architectures. Additive phenotypes with $h^2 = 0.5$ were simulated from 1,000 randomly selected causal variants with maximum allele frequency from 0.01 to 0.1 (x-axis). Normalized SNP effect-sizes were drawn from the standard normal such that each SNP explains equal variance in expectation. Box-plots show inferred h_g^2 over 40 random simulations. For the joint component model the sum of both inferred h_g^2 values is reported. A red asterisk indicates significant difference from 0.5 by z-test after correcting for ten architectures tested. Under the un-adjusted single-component model we observe both kinds of bias depending on the causal allele frequency cutoff. When causal variants are primarily rare ($MAF \leq 0.02$) the mean estimate is significantly deflated down to 0.45, whereas when causal variants are more common ($MAF \leq 0.1$) the mean estimate is significantly deflated up to 0.59. LD adjustment¹ of the single component appears to fix the downwards bias, with mean estimate no lower than 0.49 (not significantly different from 0.50) but does not completely mitigate the upwards bias, with a mean estimate up to 0.57. Splitting the data into two components for rare and common SNPs entirely removes the upwards bias but introduces downwards bias in most instances where causal variants can be common. Combining the two strategies and using two internally LD-adjusted¹ components yields completely unbiased estimates with no disease architecture exhibiting h_g^2 significantly different from 0.5.




Figure S18. Heritability estimates in simulation with standard allelic effect-sizes. Distribution h_g^2 inferred by four variance-component models is shown over a range of disease architectures. Additive phenotypes with $h^2 = 0.5$ were simulated from 1,000 randomly selected causal variants with maximum allele frequency from 0.01 to 0.1 (x-axis). Allelic effect-sizes were drawn from the standard normal such that common SNPs explain more variance in expectation. Box-plots show inferred h_g^2 over 40 random simulations. For the joint component model the sum of both inferred h_g^2 values is reported. A red asterisk indicates significant difference from 0.5 by z-test after correcting for ten architectures tested.

We considered whether the SNPs used to construct the GRM should be normalized by their observed variance or the expected variance $2p(1-p)$ based on the minor allele frequency p . We performed simulations for the two normalization schemes and two effect-size distributions. Under the infinitesimal model where every variant explains the same amount of phenotypic variance in expectation, we observed no differences between the normalizations for any class of SNPs. Under the neutral model where effect-size is proportional to the minor allele frequency, we observed a significant difference between the two normalizations when rare variants were included in the analysis, with the $2p(1-p)$ scaling resulting in a significant upwards bias. These findings indicate that rare variants have slight but consistent deviations from Hardy-Weinberg equilibrium that can affect the variance-component estimate under the $2p(1-p)$ normalization. To account for this, we use the observed variance to normalize markers in all analyses of rare variants.




Figure S19. Estimates of functional enrichment under the null. We simulated a polygenic disease architecture with MAF-independent imputed causal SNPs uniformly drawn from all functional categories, corresponding to no enrichment. Simulated phenotypes were tested using the variance-component method (top left) from 3000 simulations; P -value enrichment (top right) from 100 simulations; stratified QQ-plot (bottom left) from 100 simulations; FGWAS (bottom right) from 100 converged simulations (out of ~ 800 total). FGWAS plot contains mean (red point); $1.96\times$ standard error (black line); and density function for the full distribution shown in gray. All methods showed no enrichment except FGWAS, which exhibited upward bias at smaller categories due to enrichment being restricted to the 0-1 scale.




Figure S20. Partitioning of h_g^2 with DHS centers enriched. Causal effect-sizes were sampled such that center of DHS (1% of genome) explains 25% of h^2 and remainder of DHS (15% of genome) explains 75% of h^2 . Box-plots shown % h^2 over 200 simulations with MAF-independent causal variants.




Figure S21. Estimates of functional enrichment from single causal category. We simulated a polygenic disease architecture with MAF-independent imputed causal SNPs drawn from a single functional category, corresponding to complete enrichment of the respective category. Simulated phenotypes were tested using the variance-component method (top left) from 1000 simulations; P -value enrichment (top right) from 100 simulations; stratified QQ-plot (bottom left) from 100 simulations; FGWAS (bottom right) from 100 converged simulations (out of ~ 800 total). FGWAS plot contains mean (red point); $1.96\times$ standard error (black line); and density function for the full distribution shown in gray. Stratified QQ-plot and P -value enrichment sub-plots show $1.96\times$ standard error as shaded regions. In the DHS-causal scenario, GWAS-based methods underestimated the enrichment; while in the Coding-causal scenario, GWAS-based methods overestimated enrichment from other correlated categories. For each method, only the Coding causal and DHS causal scenarios are shown, additional simulations appear in Fig. S6, S7, S23, S24, S26, S27.

Stratified QQ-Plot




Figure S22. Stratified QQ-plot from realistic simulations. Stratified QQ-plots² display association statistics from variants in LD with each functional category in a probability plot, and assess significant enrichment of a given category visually or by a non-parametric test. The method accounts for LD by computing the sum of r^2 correlations between each GWAS SNP and all neighboring variants (within 1Mbp, including the SNP itself) belonging to a given functional category. A GWAS SNP is then considered part of a category if the corresponding score is ≥ 1 and QQ-lines are computed, separately, for each SNP in a category. We implemented this method as described in Schork et al.², using the European 1000 Genomes samples as the LD reference. As required, intergenic variants were defined as those having a score of zero to every other category, and we refer to them as “baseline” here to distinguish from the functionally intergenic category. Association statistics for each category were divided by the λ_{GC} observed in the baseline variants. Realistic traits were simulated in a 33,000 sample cohort with 8,300 causal SNPs where DHS and coding variants explaining 79% and 8% of h_g^2 , respectively (no enrichment for other categories). Phenotypes and GWAS summary statistics were computed in a cohort of 32,000 samples. DHS appears to be the least enriched non-baseline category, while UTR, Promoter, and Intron appear falsely enriched due to LD to the truly causal Coding category. Shaded regions show standard error from 50 replicates. Under the null, the method correctly identified no enrichment for any disease architecture (Fig. S19). Under the causal category scenario, the stratified QQ-plots exhibited similar patterns of false-positive enrichment for correlated categories and false-negative estimates for DHS (Fig. S21, S23, S24). While the truly causal category generally had the highest deviation from the null in all instances except DHS-causal, it was not significantly distinguishable from the other truly null categories. Patterns were similar for the low-frequency architecture, with the DHS category further falsely depleted.




Figure S23. Stratified QQ-plots enrichment from simulated enrichment (MAF-independent). Each sub-figure shows stratified QQ-plot estimate when only the title category is causal. Non-intergenic categories appear falsely enriched in most instances. See Figure S22 for method and simulation details.




Figure S24. Stratified QQ-plots enrichment from simulated enrichment (low-frequency). Each sub-figure shows stratified QQ-plot estimate when only the title category is causal. Non-intergenic categories appear falsely enriched in most instances. See Figure S22 for method and simulation details.




Figure S25. Enrichment from FGWAS under the null. Recently, Pickrell et al.³ proposed a Bayesian hierarchical model that iteratively estimates category-specific enrichment priors and individual SNP association posteriors, implemented in the FGWAS software (see Web Resources). It's important to note that the main focus of this work was to identify functional enrichment at strongly associated variants, which is a fundamentally different question from enrichment in polygenic h^2_g . With this in mind, we provide comparisons to FGWAS here for completeness, and as a measure of the expected difference between polygenic architecture and the strong associations. We computed the estimates of $P(\text{causal})$, the probability that a SNP from the given annotation is causal, by running FGWAS in the “-print -p 0” mode to return individual SNP posteriors and then summing the posteriors over all SNPs in a given annotation divided by the sum of posteriors over all SNPs. We also report the odds-ratio estimate of enrichment inferred by FGWAS where appropriate. We ran FGWAS on our simulated phenotypes with window size set such that one causal variant is present in expectation ($-k$ 500), to match the methodological assumptions. Due to computational constraints, FGWAS was only evaluated on chromosome 1 and any non-converging runs were excluded. In the null simulations, FGWAS was significantly upwardly biased for the smaller categories, perhaps due to the underlying metric having high variance and being restricted to the 0-1 scale or due to the large number of simulations not converging (Fig. S25A). The low-frequency and mixed architectures were generally similar to the MAF-independent architecture (Fig. S25B,C). For the causal simulations, the $P(\text{causal})$ at the true causal category was typically the highest but still underestimated by over 50%, with the larger non-causal categories also falsely identified as causal (Fig. S21, S26). This was most apparent when DHS is truly causal, with the intron and intergenic categories being indistinguishable from DHS. On the other hand, under the low-frequency architecture, estimates of $P(\text{causal})$ were not substantially different from the null; matching the overall category size regardless of true enrichment (Fig. S27). The FGWAS estimate has previously been shown to be unbiased when annotations are randomly sampled from the genome⁴, and we suspect that the complex LD between contiguous categories results in the bias observed here. Each subplot shows estimates of enrichment from simulated phenotypes with no enrichment under different causal-variant architectures. Depending on the causality, smaller categories (Coding, UTR, Promoter) yield upward bias due to individual estimates being bounded to 0-1. The fraction of simulations that converged was 15%, 38%, and 16% respectively.




Figure S26. FGWAS estimates from simulated enrichment (MAF-independent). Each subfigure shows the FGWAS estimate when only the title category is causal. Though the truly causal category is typically identified as most enriched, other categories (particularly the larger DHS/Intron/Intergenic) exhibit upward bias. The fraction of simulations that converged was 10% on average per category. See Figure S25 for method and simulation details.




Figure S27. FGWAS estimates from simulated enrichment (low-frequency). Each sub-figure shows the FGWAS estimate when only the title category is causal. Unlike the MAF-independent architecture, estimates of causality are not substantially different from the null category size. The fraction of simulations that converged was 30% on average per category. See Figure S25 for method and simulation details.




Figure S28. Enrichment from GWAS summary-statistics across 11 traits. Enrichment estimates from three GWAS-based methods are shown averaged over 11 traits (top) and for PGC2 Schizophrenia (bottom). Estimates for most enriched category were inconsistent across methods both in the WTCCC traits and in PGC. Shaded regions for P -value enrichment and QQ-plot, gray bars for FGWAS correspond to $1.96\times$ standard error. FGWAS did not converge for BD, HT, and SP and they were excluded from the plot. We did not observe a clear consensus across the methods, with P -value enrichment showing promoter variants as significantly enriched; stratified QQ-plots showing significant enrichment in all non-intergenic categories; and FGWAS identifying coding variants as significantly enriched (Fig. 4A, S28). Likewise, in analyses of PGC2, none of the GWAS-based methods identified substantial enrichment at DHS variants (Fig. S28) nor did they agree on the most enriched category: promoter/coding for P -value enrichment; coding/UTR for stratified qq-plot; and promoter for FGWAS. This is consistent with our findings in realistic simulations, with stratified QQ-plots having similar results to P -value enrichment (Fig. 4B, S22, results from FGWAS were not shown due to lack of convergence).




Figure S29. Partitioning of h_g^2 with true DHS and coding enrichment. Inferred h_g^2 enrichment from disease architecture mimicking observed DHS and coding enrichment in real data. Due to computational restrictions, enrichment was estimated from a random 15,000 samples of the 33,000 sample simulated GWAS cohort. Colored bars show the induced enrichment. Boxplots show the distribution of inferred enrichment over 50 trials.

Phenotype	Label	Prevalence	Cases	Controls	Genotyped SNPs	Imputed SNPs
WTCCC2:						
Schizophrenia	SP	0.010	2698	5458	394992	4345606
Ankylosing spondylitis	AS	0.003	1783	5239	408616	6162624
Multiple sclerosis	MS	0.001	9315	5211	396469	5795523
Ulcerative colitis	UC	0.001	2495	5428	447905	4620390
WTCCC:						
Bipolar disorder	BD	0.005	1550	2666	143054	4192374
Coronary artery disease	CAD	0.060	1746	2668	139567	4190156
Crohns disease	CD	0.001	1542	2662	146952	4199232
Hypertension	HT	0.050	1730	2669	139541	4185735
Rheumatoid arthritis	RA	0.005	1664	2664	143732	4190217
Type 1 diabetes	T1D	0.005	1746	2668	139206	4184291
Type 2 diabetes	T2D	0.080	1641	2671	142027	4195404
Other:						
Schizophrenia	PGC2	0.010	24926	33271	Varies	4-5 million
Schizophrenia	SWE ex-chip	0.010	5010	6197	238652	NA

Table S1. Datasets analyzed. Number of samples and markers for each dataset analyzed.

Cohort	Cases	Controls
boco	1754	2121
bulb	192	595
denm	462	449
dubl	259	828
edin	363	281
ersw	260	311
lie5	486	383
mgs2	2583	2444
pewb	564	1779
ucla	688	598
clo3	2105	1975
cou3	530	678
egcu	234	1152
ersw	265	319
swe5	1764	2581
swe6	975	1145
umeb	341	577
umes	193	704
bulb	195	608
butr	608	613
cims	67	65
clm2	3426	4085
lie2	133	269
msaf	325	139
pewb	574	1812
pews	150	236
aarh	876	871
boco	1773	2161
fi6	360	1082
gras	1067	1169
lacw	157	245
lie5	497	389
ucla	700	607

Table S2. PGC2 datasets analyzed.

Variant class	Homogenous	All
All coding	104,240	110,331
Singleton coding	19,860	19,329
Rare coding (MAF < 0.01, non-singleton)	64,040	70,569
Common coding (MAF \geq 0.01)	20,340	20,433

Table S3. Summary of exome-chip data. Number of polymorphic variants by coding class and sub-cohort in the Swedish schizophrenia samples.

Category	Description	% physical	% 1000G	% array	% imputed
Coding (non-UTR)	Overlaps a coding exon.	1.1%	0.9%	0.9%	0.5%
UTR	Overlaps a 5' or 3' untranslated region.	1.0%	0.9%	1.0%	0.8%
Promoter	Within 2kbp of a transcription start site.	2.5%	2.6%	2.2%	2.2%
DHS	Overlaps DHS region observed in any cell-type.	14.6%	16.4%	23.3%	15.7%
Intron	Overlaps an intron.	29.1%	28.6%	26.8%	28.8%
Intergenic	All other intergenic variants.	51.8%	50.5%	44.8%	52.0%

Table S4. Coding and regulatory annotation categories. Description of functional categories and fraction occupied, respectively, by physical genome; all 1000 Genomes SNPs; average array SNPs; average imputed 1000G SNPs.

WTCCC1 Genotyped: Affymetrix				
Annotation	MAF	INFO	LD score	Cons
Coding	0.2330	NA	116.4	1.076
UTR	0.2388	NA	104.1	0.560
Promoter	0.2435	NA	118.6	0.231
DHS	0.2462	NA	92.6	0.346
Intron	0.2450	NA	111.0	0.177
Intergenic	0.2489	NA	116.9	0.135
WTCCC2 Imputed: Affymetrix				
Annotation	MAF	INFO	LD score	Cons
Coding	0.1700	0.9730	111.0	1.191
UTR	0.1773	0.9749	100.2	0.620
Promoter	0.1780	0.9739	114.5	0.266
DHS	0.1836	0.9775	89.0	0.388
Intron	0.1817	0.9776	108.2	0.194
Intergenic	0.1846	0.9773	111.6	0.148
WTCCC2 Imputed: Illumina				
Annotation	MAF	INFO	LD score	Cons
Coding	0.1672	0.9745	91.7	1.525
UTR	0.1735	0.9758	85.8	0.816
Promoter	0.1749	0.9751	97.1	0.358
DHS	0.1798	0.9778	79.2	0.498
Intron	0.1780	0.9791	94.7	0.254
Intergenic	0.1810	0.9780	101.3	0.188

Table S5. Functional category features. For each genotyping platform and functional category, the following features are reported: minor allele frequency (MAF), imputation quality (INFO), average number of LD partners (LD score), and GERP conservation score (Cons).

Annotation	% SNPs	Imputed		Genotyped	
		% Effective SNPs	% SNPs	% Effective SNPs	% Effective SNPs
Coding	0.5%	0.5%	1.0%		2.3%
UTR	0.8%	0.8%	1.0%		2.4%
Promoter	2.2%	2.0%	2.3%		4.8%
DHS	15.7%	18.9%	23.6%		33.6%
Intron	28.6%	29.8%	27.1%		23.2%
Other	52.2%	47.9%	45.0%		33.7%
DHS-Cell-Unique	4.0%	4.4%	NA		NA
DHS-DGF	7.8%	9.5%	NA		NA
DHS-Enhancer	3.2%	4.2%	NA		NA
DHS-Narrowed 1%	1.1%	1.3%	NA		NA
DHS-Narrowed 5%	5.2%	6.1%	NA		NA
DHS-Narrowed 10%	10.3%	12.1%	NA		NA

Table S6. Effective % of SNPs in analyzed categories. For each functional category analyzed, effective number of imputed SNPs was computed using LD in 1000G EUR samples^{5,6}; defined as the number of SNPs divided by the average sum of r^2 between a SNP in the category and every other SNP in a 1Mbp window. Lower panel shows estimates from functional categories analyzed only in imputed data.

Table S7. Cell types analyzed. Excel spreadsheet detailing cell types and tissues used for cell-type specific DHS analysis.

Category	% SNPs	1x noise			2x noise		
		% h_g^2 (se)	SD	REML SE	% h_g^2 (se)	SD	REML SE
CODING	0.6%	0.2% (0.5%)	5.5%	5.0%	0.4% (0.6%)	5.8%	5.2%
DHS	15.8%	16.0% (1.9%)	19.4%	17.9%	18.5% (1.7%)	17.2%	18.4%
PROMOTER	2.4%	1.4% (0.7%)	7.0%	6.5%	2.6% (0.7%)	6.9%	6.7%
UTR	0.9%	1.4% (0.5%)	4.8%	5.1%	1.5% (0.6%)	5.7%	5.3%
INTRON	29.1%	29.0% (1.1%)	10.8%	10.4%	28.7% (1.1%)	10.8%	10.7%
OTHER	51.3%	52.0% (1.1%)	11.4%	11.2%	48.3% (1.1%)	11.3%	11.4%

Table S8. Partitioned null h_g^2 with simulated imputation noise. Null phenotypes were simulated from SNPs with realistic imputation noise (proportional to imputation INFO score) added and % h_g^2 inferred using functional components without noise; corresponding to a scenario where genotypes are imputed with some inaccuracy. Under the assumption that INFO score is a reasonable proxy for imputation accuracy, substantial differences in imputation between categories would be expected to yield biased estimates. However, no significant deviations from the null were observed. As in previous simulations, a polygenic quantitative trait was constructed from 8,300 randomly selected causal variants for individuals in the WTCCC2:AS cohort. For each causal SNP s and corresponding INFO (imputation accuracy) score i_s , normally distributed noise was added to create a new SNP s' such that s had an R^2 of i_s with s' . A polygenic trait with $h_g^2 = 0.50$ and no functional enrichment was then simulated from the noisy genotypes (identical to a model where phenotypes come from clean genotypes and the GRM is constructed from noisy ones). The “2x noise” column corresponds to a more extreme simulation where the added noise was double that observed in the real data (new $i_s = 1 - 2(1 - i_s)$). The empirical standard deviation (SD) and the average analytical standard error (REML SE) is also shown for each scenario and do not deviate substantially. All estimates computed from 100 random simulations.

Category	1x noise % h_g^2 (se)	2x noise % h_g^2 (se)
CODING	99.5% (0.8%)	100.3% (0.9%)
DHS	95.7% (2.4%)	95.4% (2.4%)

Table S9. Partitioned causal h_g^2 with simulated imputation noise. Simulations as described in Table S8 but with 100% h_g^2 in the listed category.

Category	λ_{GC}	% h_g^2	se	P -value	adjusted se	adjusted P -value
Coding	1.26	7.5%	2.0%	4.74e-04	2.2%	1.83e-03
UTR	1.34	6.6%	2.0%	4.28e-03	2.4%	1.36e-02
Promoter	1.45	6.2%	2.6%	1.25e-01	3.1%	2.02e-01
DHS	1.32	79.5%	6.6%	3.64e-22	7.6%	3.74e-17
Intron	1.39	1.5%	3.9%	5.48e-12	4.7%	4.89e-09
Intergenic	1.70	-3.1%	4.0%	2.84e-42	5.3%	1.53e-25

Table S10. Meta-analysis adjusted for shared controls. We evaluated potential biases due to the use of shared controls by shifting the functional categories and performing the entire genotyped meta-analysis procedure to compute an empirical null distribution. Specifically, over 1,000 consecutive indices, we shifted all functional annotations ahead by 2MB (moving regions that crossed the chromosome boundary into the next chromosome) thereby preserving the total h_g^2 , total sample relatedness, and relative dependence between categories but permuting any relationship to true function. For each shifted annotation, we re-computed GRMs from the genotyped data and estimated functional enrichment within each trait, as well as the meta-analysis value across all 11 traits, yielding $1,000 \times 6$ shifted meta-analysis estimates. We observed no enrichment or inflation of P -values within each study (Table S11), further supporting the robustness of the empirical standard error. We did observe inflation in the meta-analysis P -values ranging from λ_{GC} of 1.26 (coding) to 1.70 (intergenic). We adjusted the standard errors observed in real data by the corresponding $\sqrt{\lambda_{GC}}$, which yielded adjusted P -values that remained significant for all categories but UTR (Table S10). For each functional category, the empirical inflation of p-values due to shared controls (λ_{GC}) is reported. The raw meta-analysis estimate of h_g^2 , standard error, and enrichment P -value is shown for imputed SNPs; followed by the corresponding λ_{GC} adjusted estimates.

Category	avg. enrichment	avg. Z-score
Coding	0.98	-0.04
UTR	1.01	-0.04
Promoter	1.04	-0.01
DHS	0.99	-0.02
Intron	1.00	0.00
Intergenic	1.00	0.00

Table S11. Estimates of enrichment from shifted regions. For each category, the average enrichment and Z-score observed in $h_{\frac{2}{g}}$ estimates on real phenotypes and shifted functional annotations. Results averaged across 1,000 shifts and all traits.

Annotation	Genotyped			Imputed		
	% h_g^2 (s.e.)	Enrichment (s.e)	P -value	% h_g^2 (s.e.)	Enrichment (s.e.)	P -value
Coding	4% (1%)	4.12 (0.96)	1.1e-03	8% (2%)	13.84 (4.12)	1.8e-03
DHS	38% (4%)	1.63 (0.16)	1.0e-04	79% (8%)	5.07 (0.48)	3.7e-17
Promoter	5% (1%)	2.19 (0.62)	5.2e-02	6% (3%)	2.79 (1.41)	2.0e-01
UTR	4% (1%)	3.51 (0.95)	8.2e-03	7% (2%)	8.42 (3.01)	1.4e-02
Intron	23% (3%)	0.83 (0.11)	1.2e-01	2% (5%)	0.05 (0.16)	4.9e-9
Intergenic	25% (4%)	0.56 (0.08)	2.7e-08	-3% (5%)	-0.06 (0.10)	1e-20

Table S12. Components of heritability from regulatory elements in GWAS data (meta-analysis). Shared controls correction applied (see also Table S13, S10).

Annotation	Genotyped			Imputed		
	% h_g^2 (s.e.)	Enrichment (s.e)	P -value	% h_g^2 (s.e.)	Enrichment (s.e.)	P -value
Coding	4% (1%)	4.12 (0.85)	2.59e-04	8% (2%)	13.84 (3.67)	4.74e-04
DHS	38% (3%)	1.63 (0.14)	7.98e-06	79% (7%)	5.07 (0.42)	3.64e-22
Promoter	5% (1%)	2.19 (0.51)	1.94e-02	6% (3%)	2.79 (1.17)	1.25e-01
UTR	4% (1%)	3.51 (0.82)	2.21e-03	7% (2%)	8.42 (2.60)	4.28e-03
Intron	23% (2%)	0.83 (0.09)	6.40e-02	2% (4%)	0.05 (0.14)	5.48e-12
Intergenic	25% (3%)	0.56 (0.06)	4.11e-13	-3% (4%)	-0.06 (0.08)	2.84e-42

Table S13. Components of heritability from regulatory elements in GWAS data (meta-analysis). Meta-analysis estimates computed using inverse-variance weighting without shared controls correction.

Bipolar disorder ($h^2 = 0.6-0.7$)								
	Genotyped $h_g^2 = 0.26$ (0.032)				Imputed $h_g^2 = 0.24$ (0.035)			
Function	% h_g^2	(s.e.)	Enrichment	P -value	% h_g^2	(s.e.)	Enrichment	P -value
Coding	3.5%	(2.4%)	4.2	2.6e-01	4.9%	(7.2%)	9.0	5.5e-01
UTR	3.6%	(2.5%)	3.8	2.8e-01	11.6%	(7.6%)	15.3	1.5e-01
Promoter	-1.0%	(3.3%)	-0.5	3.4e-01	-11.0%	(9.4%)	-5.1	1.6e-01
DHS	34.0%	(10.3%)	1.4	3.1e-01	34.6%	(26.5%)	2.2	4.7e-01
Intron	22.9%	(8.0%)	0.9	6.2e-01	27.0%	(15.3%)	0.9	9.2e-01
Intergenic	37.0%	(8.9%)	0.8	3.3e-01	33.0%	(16.2%)	0.6	2.3e-01
Coronary artery disease ($h^2 = 0.3-0.6$)								
	Genotyped $h_g^2 = 0.31$ (0.057)				Imputed $h_g^2 = 0.25$ (0.062)			
Function	% h_g^2	(s.e.)	Enrichment	P -value	% h_g^2	(s.e.)	Enrichment	P -value
Coding	1.7%	(3.2%)	2.2	7.7e-01	7.5%	(12.5%)	14.0	5.7e-01
UTR	5.6%	(3.7%)	5.9	2.1e-01	10.5%	(13.0%)	13.8	4.6e-01
Promoter	4.5%	(5.1%)	2.0	6.6e-01	2.8%	(16.0%)	1.3	9.7e-01
DHS	41.1%	(15.4%)	1.8	2.5e-01	0.7%	(47.1%)	0.0	7.5e-01
Intron	24.5%	(12.0%)	0.9	8.4e-01	44.4%	(27.5%)	1.5	5.7e-01
Intergenic	22.6%	(13.8%)	0.5	9.3e-02	34.1%	(27.2%)	0.7	5.0e-01
Crohn's disease ($h^2 = 0.6-0.8$)								
	Genotyped $h_g^2 = 0.18$ (0.024)				Imputed $h_g^2 = 0.17$ (0.025)			
Function	% h_g^2	(s.e.)	Enrichment	P -value	% h_g^2	(s.e.)	Enrichment	P -value
Coding	3.7%	(2.5%)	4.6	2.5e-01	19.2%	(8.2%)	35.9	2.3e-02
UTR	-0.8%	(2.5%)	-0.8	4.8e-01	3.1%	(7.6%)	4.1	7.6e-01
Promoter	7.3%	(4.0%)	3.3	2.0e-01	-3.6%	(9.5%)	-1.7	5.4e-01
DHS	58.4%	(11.9%)	2.5	3.4e-03	151.7%	(27.1%)	9.7	5.2e-07
Intron	14.9%	(8.8%)	0.6	1.7e-01	-30.9%	(15.6%)	-1.1	1.3e-04
Intergenic	16.5%	(10.3%)	0.4	4.9e-03	-39.5%	(17.3%)	-0.8	1.1e-07
Hypertension ($h^2 = 0.3-0.7$)								
	Genotyped $h_g^2 = 0.37$ (0.053)				Imputed $h_g^2 = 0.33$ (0.059)			
Function	% h_g^2	(s.e.)	Enrichment	P -value	% h_g^2	(s.e.)	Enrichment	P -value
Coding	6.2%	(2.9%)	7.6	6.4e-02	25.4%	(10.5%)	47.2	1.8e-02
UTR	5.5%	(3.0%)	5.6	1.3e-01	12.7%	(9.5%)	16.7	2.1e-01
Promoter	4.9%	(4.2%)	2.2	5.1e-01	-3.0%	(11.7%)	-1.4	6.6e-01
DHS	28.3%	(11.7%)	1.2	6.8e-01	93.8%	(31.6%)	6.0	1.3e-02
Intron	19.4%	(9.4%)	0.7	4.2e-01	-32.4%	(18.6%)	-1.1	1.1e-03
Intergenic	35.6%	(10.5%)	0.8	3.4e-01	3.4%	(19.8%)	0.1	1.3e-02
Rheumatoid arthritis ($h^2 = 0.6$)								
	Genotyped $h_g^2 = 0.11$ (0.031)				Imputed $h_g^2 = 0.09$ (0.033)			
Function	% h_g^2	(s.e.)	Enrichment	P -value	% h_g^2	(s.e.)	Enrichment	P -value
Coding	-0.6%	(5.0%)	-0.8	7.7e-01	1.4%	(17.7%)	2.6	9.6e-01
UTR	7.1%	(5.7%)	7.3	2.9e-01	21.1%	(19.3%)	27.9	2.9e-01
Promoter	1.9%	(7.5%)	0.9	9.8e-01	28.3%	(24.6%)	13.2	2.9e-01
DHS	46.4%	(23.4%)	2.0	3.3e-01	162.7%	(67.4%)	10.4	2.9e-02
Intron	6.5%	(18.9%)	0.2	2.8e-01	-78.9%	(45.1%)	-2.8	1.7e-02
Intergenic	38.8%	(20.1%)	0.8	7.3e-01	-34.6%	(42.0%)	-0.7	3.8e-02
Type 1 diabetes ($h^2 = 0.9$)								
	Genotyped $h_g^2 = 0.13$ (0.030)				Imputed $h_g^2 = 0.13$ (0.032)			

Function	% h_g^2	(s.e.)	Enrichment	P -value	% h_g^2	(s.e.)	Enrichment	P -value
Coding	7.9%	(4.6%)	9.5	1.3e-01	35.0%	(16.1%)	65.3	3.2e-02
UTR	5.1%	(4.4%)	5.2	3.5e-01	-1.8%	(12.9%)	-2.4	8.4e-01
Promoter	11.0%	(6.7%)	5.0	1.9e-01	28.8%	(18.3%)	13.5	1.4e-01
DHS	28.2%	(18.0%)	1.2	7.9e-01	106.2%	(42.5%)	6.8	3.3e-02
Intron	36.7%	(14.7%)	1.4	5.1e-01	-8.3%	(26.0%)	-0.3	1.5e-01
Intergenic	11.2%	(17.1%)	0.2	4.4e-02	-59.9%	(30.8%)	-1.1	2.7e-04
Type 2 diabetes ($h^2 = 0.3-0.6$)								
Genotyped $h_g^2 = 0.37$ (0.065)				Imputed $h_g^2 = 0.42$ (0.070)				
Function	% h_g^2	(s.e.)	Enrichment	P -value	% h_g^2	(s.e.)	Enrichment	P -value
Coding	-2.0%	(3.0%)	-2.4	3.5e-01	2.5%	(8.1%)	4.7	8.1e-01
UTR	-0.7%	(3.2%)	-0.7	6.0e-01	8.7%	(8.5%)	11.4	3.5e-01
Promoter	-3.5%	(4.7%)	-1.6	2.3e-01	-3.3%	(10.3%)	-1.5	6.0e-01
DHS	69.3%	(16.0%)	3.0	4.0e-03	63.8%	(27.5%)	4.1	8.0e-02
Intron	26.1%	(11.4%)	1.0	9.4e-01	17.1%	(17.4%)	0.6	5.1e-01
Intergenic	10.7%	(13.6%)	0.2	1.0e-02	11.1%	(17.2%)	0.2	1.7e-02
Multiple sclerosis ($h^2 = 0.3-0.8$)								
Genotyped $h_g^2 = 0.19$ (0.009)				Imputed $h_g^2 = 0.17$ (0.009)				
Function	% h_g^2	(s.e.)	Enrichment	P -value	% h_g^2	(s.e.)	Enrichment	P -value
Coding	6.4%	(1.7%)	3.6	6.2e-03	5.5%	(2.9%)	9.4	9.5e-02
UTR	3.9%	(1.4%)	3.2	6.3e-02	8.1%	(3.1%)	9.4	1.9e-02
Promoter	6.1%	(2.0%)	2.4	7.4e-02	11.7%	(4.0%)	5.0	1.8e-02
DHS	33.1%	(5.3%)	1.3	1.1e-01	77.7%	(9.4%)	4.9	5.5e-11
Intron	24.1%	(4.0%)	0.9	3.1e-01	1.5%	(5.7%)	0.1	9.1e-07
Intergenic	26.4%	(4.2%)	0.6	3.2e-04	-4.5%	(5.7%)	-0.1	1.0e-16
Ankylosing spondylitis ($h^2 > 0.90$)								
Genotyped $h_g^2 = 0.18$ (0.028)				Imputed $h_g^2 = 0.14$ (0.027)				
Function	% h_g^2	(s.e.)	Enrichment	P -value	% h_g^2	(s.e.)	Enrichment	P -value
Coding	6.9%	(4.8%)	3.9	2.9e-01	1.5%	(10.4%)	2.6	9.3e-01
UTR	11.4%	(4.6%)	9.2	2.7e-02	20.9%	(12.0%)	24.5	9.6e-02
Promoter	5.2%	(5.7%)	2.0	6.5e-01	7.5%	(13.5%)	3.2	7.1e-01
DHS	41.8%	(16.1%)	1.7	2.8e-01	106.3%	(33.4%)	6.7	6.8e-03
Intron	14.9%	(11.7%)	0.5	2.6e-01	-23.6%	(20.6%)	-0.8	1.1e-02
Intergenic	19.8%	(12.7%)	0.5	8.6e-02	-12.6%	(20.2%)	-0.2	1.5e-03
Schizophrenia ($h^2 = 0.7-0.8$)								
Genotyped $h_g^2 = 0.20$ (0.025)				Imputed $h_g^2 = 0.18$ (0.024)				
Function	% h_g^2	(s.e.)	Enrichment	P -value	% h_g^2	(s.e.)	Enrichment	P -value
Coding	1.9%	(2.9%)	2.6	6.8e-01	7.7%	(6.6%)	14.2	2.8e-01
UTR	2.5%	(3.1%)	2.6	6.2e-01	0.8%	(6.3%)	1.0	1.0e 00
Promoter	7.4%	(4.4%)	3.4	2.4e-01	-9.7%	(7.7%)	-4.2	1.2e-01
DHS	37.6%	(13.3%)	1.6	2.7e-01	44.4%	(22.8%)	2.8	2.1e-01
Intron	26.6%	(9.4%)	1.0	9.8e-01	37.3%	(14.0%)	1.3	5.3e-01
Intergenic	23.9%	(10.6%)	0.5	3.5e-02	19.6%	(14.1%)	0.4	2.2e-02
Ulcerative colitis ($h^2 = 0.5$)								
Genotyped $h_g^2 = 0.17$ (0.017)				Imputed $h_g^2 = 0.14$ (0.016)				
Function	% h_g^2	(s.e.)	Enrichment	P -value	% h_g^2	(s.e.)	Enrichment	P -value

Coding	4.7%	(2.5%)	6.2	1.2e-01	7.6%	(5.9%)	14.5	2.3e-01
UTR	4.3%	(2.6%)	4.5	2.1e-01	-1.4%	(5.7%)	-1.7	7.0e-01
Promoter	8.7%	(3.7%)	4.0	7.3e-02	23.8%	(7.9%)	10.6	6.5e-03
DHS	43.3%	(10.9%)	1.9	6.5e-02	93.5%	(19.4%)	6.0	6.0e-05
Intron	21.2%	(7.6%)	0.8	4.5e-01	-5.6%	(11.5%)	-0.2	2.8e-03
Intergenic	17.9%	(8.7%)	0.4	1.1e-03	-18.0%	(12.4%)	-0.3	1.5e-08

Table S14. Components of heritability from regulatory elements in GWAS data. Family-based h^2 (from literature), total h_g^2 , and function-specific h_g^2 of liability is reported for eleven traits. Enrichment computed over the % of SNPs in each category and P -value computed from Z-score. For auto-immune traits (CD,RA,T1D,MS,AS,UC) the well-studied MHC locus was removed from analyses. By inverse-variance meta-analysis, the average total genotyped $h_g^2 = 0.17$ (0.01) and imputed $h_g^2 = 0.19$ (0.01) for a nominally significant difference of $P=0.03$. Using flat weights instead yielded % h_g^2 DHS = 85% with standard deviation of 48% (corresponding to both trait and sampling variation) and root mean squared analytical standard error of 36% (corresponding to estimated sampling variation only), yielding a standard deviation of $\sqrt{0.48^2 - 0.36^2} = 32\%$ in the true unobserved values. All traits with % h_g^2 estimates $> 100\%$ (CD, RA, T1D, AS) have compensatory components with negative estimates.

Category	Constrained			Standard		
	fraction h_g^2 (se)	enrichment (se)	PV	fraction h_g^2 (se)	enrichment (se)	PV
Coding	0.052 (0.019)	9.521 (3.418)	1.27e-02	0.075 (0.020)	13.838 (3.673)	4.74e-04
UTR	0.053 (0.019)	6.801 (2.443)	1.76e-02	0.066 (0.020)	8.417 (2.596)	4.28e-03
Promoter	0.069 (0.025)	3.126 (1.109)	5.52e-02	0.062 (0.026)	2.792 (1.168)	1.25e-01
DHS	0.710 (0.064)	4.532 (0.407)	3.82e-18	0.795 (0.066)	5.072 (0.421)	3.64e-22
Intron	0.061 (0.038)	0.211 (0.131)	1.74e-09	0.015 (0.039)	0.053 (0.137)	5.48e-12
Intergenic	0.046 (0.039)	0.088 (0.075)	9.68e-34	-0.031 (0.040)	-0.059 (0.078)	2.84e-42

Table S15. Constrained REML estimate of h_g^2 . Comparison of constrained analysis (where components estimating h_g^2 below zero are dropped from the analysis) and the standard un-constrained results. All values computed from meta-analysis over 11 traits. No shared-controls correction applied.

Enrichment	Coding	DHS	Promoter	UTR	Intron	Intergenic	Entropy (H)
Promoter (imputed)	0.00%	2.35%	0.14%	0.01%	7.94%	25.98%	0.65
Coding (imputed)	0.04%	2.28%	0.05%	0.01%	7.69%	25.17%	0.64
All categories (genotyped)	0.02%	6.02%	0.11%	0.03%	6.49%	13.03%	0.62
DHS (imputed)	0.00%	12.45%	0.01%	0.00%	2.02%	6.60%	0.52
All categories (imputed)	0.04%	12.45%	0.14%	0.05%	0.44%	-1.59%	0.30

Table S16. Theoretical entropy of functional partitions. Our estimates of the relative significance of different h_g^2 enrichment scenarios were directly dependent on the standard error and overall sample size analyzed. Here, we consider an alternative figure of merit which relies only on the fraction of h_g^2 in each category. We borrow from information theory the concept of entropy, which is a measure of uncertainty in the distribution of a random variable. Given $P(X_i)$, the probability mass function of a random variable, entropy can be quantified as $H = - \sum_{i=1}^a P(X_i) \log(P(X_i))$. Depending on the distribution and log-base, this is equivalent to the number of bits required to encode an observation, with higher entropy implying lower predictability. Applying this to functional categories, we define $P(X_i)$ as the joint probability that a SNP falls into the given category and is causal. Assuming that $\%h_{gi}^2$ corresponds to the probability of causality in category i , we compute $P(X_i) = \%SNP_i \times \%h_{gi}^2$. We then compute the entropy as outlined previously. Table S16 demonstrates the resulting entropy from multiple enrichment scenarios observed in the 11 traits, with entropy inversely correlated to the individual category significance. Highest entropy was computed for an enrichment scenario that only accounted for the (least significant) promoter category, and lowest entropy was observed for an enrichment scenario that accounted for all six categories. Interestingly, the six-category genotyped enrichment yielded higher entropy than a hypothetical DHS-only imputed enrichment. This formulation of “functional entropy” provides a standard metric for comparing real and hypothetical enrichment scenarios completely independent of sample size and data platform. Each row indicates a different enrichment scenarios observed in the 11 traits, with the rows listing individual annotations corresponding to an enrichment only at that category and no enrichment in other categories. Each column then lists the probability of a SNP being causal ($\% h_g^2 \times \% SNP$ for that category), as well as the resulting entropy computed as $H = - \sum p \times \log(p)$.

Category	A: 1000G imputed	B: Genome-wide significant	C: Known from NHGRI
	% SNPs	% SNPs (enrichment)	% SNPs (enrichment ¹)
Coding	0.5%	1.7% (3.16)	8.5% (16.98)
UTR	0.8%	1.7% (2.20)	2.6% (3.25)
Promoter	2.2%	2.3% (1.04)	7.5% (3.39)
DHS	15.7%	14.3% (0.91)	27.4% (1.74)
Intron	28.8%	30.7% (1.07)	25.5% (0.88)
Intergenic	52.0%	49.3% (0.95)	28.6% (0.55)

¹Does not account for null distribution of NHGRI SNPs.

Table S17. Functional enrichment from GWAS hits. Fraction of SNPs partitioned into each category shown for (A) all 1000 Genomes imputed SNPs; (B) genome-wide significant imputed SNPs (single best association in 1MB locus); and (C) known associated SNPs from NHGRI catalog. Enrichments computed relative to 1000G imputed fractions, all values computed from union of 11 traits.

Annotation	% h_g^2 (s.e.)	Enrichment (s.e)	<i>P</i> -value
Coding	0.026 (0.014)	4.206 (2.192)	1.44e-01
UTR	0.075 (0.014)	8.934 (1.653)	1.59e-06
Promoter	0.040 (0.017)	1.814 (0.760)	2.84e-01
DHS	0.509 (0.047)	3.154 (0.291)	1.40e-13
Intron	0.193 (0.028)	0.651 (0.096)	2.82e-04
Intergenic	0.149 (0.029)	0.294 (0.057)	1.94e-35

Table S18. Components of heritability from regulatory elements in PGC2 schizophrenia.

Category	% category	% h_g^2	% DHS h_g^2 (se)	% DHS SNP	enrichment to DHS (se)	PV
DHS-Coding	27.4%	5% (1%)	5% (1%)	0.9%	5.30 (1.34)	1.35e-03
DHS-UTR	31.2%	5% (1%)	4% (1%)	1.4%	2.62 (0.93)	8.16e-02
DHS-Promoter	29.8%	9% (2%)	9% (2%)	3.9%	2.25 (0.47)	7.90e-03
DHS-Intron	NA	40% (3%)	35% (2%)	39.6%	0.87 (0.06)	3.74e-02
DHS-Intergenic	NA	51% (4%)	48% (2%)	54.2%	0.89 (0.04)	1.05e-02
non-DHS	NA	-16% (5%)	NA	NA	NA	NA

Table S19. Functional enrichment of main categories within DHS category. The extended DHS category was sub-partitioned into five annotations, and h_g^2 reported. % category reports the percent of main category covered by DHS. The remaining non-DHS category was significantly negative ($P = 0.002$), likely due to underestimating standard errors.

Tissue type	Cell type	Genotyped Autoimmune	Imputed Autoimmune	Genotyped Non-autoimmune
Blood	T Cell	5.8 (4.2e-06)	10.2 (1.3e-12)	2.1 (3.5e-01)
Blood	Leukemia Cells	3.5 (6.7e-06)	4.7 (5.3e-10)	1.0 (9.8e-01)
Blood	Lymphoblastoid Cell	3.3 (1.1e-05)	4.9 (5.4e-11)	1.0 (9.4e-01)
Fetal Kidney	Fetal Right Renal Pelvis	5.4 (1.4e-04)	8.2 (5.7e-08)	1.5 (7.4e-01)
Bone Marrow	Monocyte	4.1 (1.6e-04)	5.7 (2.2e-07)	1.3 (7.6e-01)
Blood	CD8 Primary Cell	3.0 (3.0e-04)	5.4 (1.8e-10)	1.0 (9.6e-01)
Fetal Thymus	Fetal Thymus Cell	2.6 (4.0e-04)	4.5 (3.2e-09)	0.8 (6.6e-01)
Blood	CD4 Primary Cell	2.3 (9.5e-04)	3.1 (6.5e-06)	0.9 (8.7e-01)
Blood	CD14 Primary Cell	2.7 (1.1e-03)	3.2 (2.8e-04)	1.3 (7.4e-01)
Liver	Hliver Cell	3.7 (1.4e-03)	6.4 (2.8e-08)	-0.3 (2.1e-01)
Fetal Kidney	Fetal Left Renal Cortex Cell	4.8 (2.0e-03)	8.3 (2.6e-07)	1.6 (7.1e-01)
Bone Marrow	Blast Cell	2.9 (2.1e-03)	5.1 (9.1e-09)	2.4 (9.0e-02)
Fetal Muscle	Fetal Back Muscle Cell	5.6 (6.5e-03)	9.5 (2.5e-08)	2.9 (2.3e-01)
Blood	CD34 Primary Cell	1.7 (9.9e-03)	1.7 (1.5e-02)	0.7 (3.9e-01)
Blood	CD34 Mobilized Primary Cell	0.1 (3.0e-02)	0.3 (1.2e-01)	1.2 (6.6e-01)
Bone Marrow	Erythroleukemic Cell	2.3 (3.8e-02)	3.2 (4.7e-04)	0.5 (5.4e-01)
Fetal Lung	Fetal Left Lung Cell	0.2 (3.9e-02)	-0.1 (1.6e-02)	1.1 (8.4e-01)
Blood	Lymphocyte	1.7 (4.0e-02)	2.4 (3.5e-04)	0.7 (4.7e-01)
Fetal Kidney	Fetal Left Renal Pelvis	2.3 (4.7e-02)	3.2 (3.7e-03)	0.9 (8.8e-01)
Fetal Large Intestine	Fetal Large Intestine Cell	1.6 (4.9e-02)	2.7 (2.2e-06)	0.9 (6.9e-01)

Table S20. Cell-type and phenotype specific DHS enrichment. Fold-enrichment of h_g^2 relative to SNPs reported for cell-types DHSs observed as significant in genotype data (without adjusting for 83 cell-types tested). Enrichment was measured in comparison to h_g^2 at DHS regions, accounting for the background DHS enrichment. Results shown separately from meta-analysis of 6 autoimmune traits and 5 non-autoimmune traits. No shared-controls adjustment applied.

Cell type	AS	CD	MS	RA	T1D	UC
Monocyte	9.3% (2.8)	9.2% (3.1)	14.8% (4.5)	20.7% (7.0)	11.6% (3.8)	13.8% (4.7)
Fetal Right Renal Pelvis	5.5% (2.7)	5.0% (3.3)	13.7% (7.0)	12.2% (7.8)	6.0% (3.9)	11.6% (7.6)
Lymphoblastoid Cell	35.1% (4.2)	15.2% (2.1)	35.8% (4.4)	28.3% (3.8)	12.5% (1.7)	29.9% (4.1)
CD8 Primary Cell	23.3% (3.1)	7.8% (1.2)	33.6% (4.5)	14.4% (2.2)	56.4% (8.7)	28.4% (4.4)
Fetal Thymus Cell	20.3% (2.1)	15.7% (1.8)	34.8% (3.6)	-2.3% (-0.3)	23.4% (2.8)	30.5% (3.5)
T Cell	19.2% (7.2)	11.3% (5.0)	15.9% (6.1)	7.9% (3.5)	NA	15.1% (7.0)
Leukemia Cells	10.5% (1.5)	19.3% (2.9)	29.8% (4.1)	19.9% (3.0)	30.2% (4.6)	29.5% (4.6)
Mean enrichment:	(3.4)	(2.8)	(4.9)	(3.9)	(4.2)	(5.1)

Table S21. Cell-type and phenotype specific DHS enrichment by trait. For cell-types reported as significant in Table 1, % h_g^2 and fold-enrichment relative to DHS is shown for each autoimmune trait, estimated from genotyped data.

% genome	% h_g^2 univar	Joint with main categories		
		% h_g^2 (se)	enrichment (se)	<i>P</i> -value
1%	0.610	0.198 (0.040)	18.094 (3.655)	2.91e-06
5%	0.853	0.415 (0.070)	7.971 (1.335)	1.76e-07
10%	0.948	0.704 (0.073)	6.884 (0.717)	2.35e-16
16% (all DHS)	0.985	0.795 (0.066)	5.072 (0.421)	3.64e-22

Table S22. h_g^2 from narrowed DHS regions. DHS regions were narrowed (to the center of the region) to achieve set % of genome, and h_g^2 estimates are reported from a single DHS component (univar) as well as jointly with the five other main components. For comparison, a randomly sampled 16% of SNPs yielded an average % h_g^2 univar of 0.86.

Variant class (and SNPs in LD)	All h_g^2 (se)	Hom. h_g^2 (se)	Hom. h_{gLD}^2 (se)
All	0.307 (0.027)	0.366 (0.038)	0.370 (0.040)
GWAS chip	0.273 (0.020)	0.314 (0.028)	0.317 (0.042)
Exome chip	0.116 (0.022)	0.157 (0.032)	0.158 (0.034)
Variant class (exclusive)	All h_g^2 (se) P -value	Hom. h_g^2 (se) P -value	Hom. h_{gLD}^2 (se) P -value
GWAS chip	0.242 (0.020)	0.282 (0.029)	0.291 (0.028)
Exome chip	0.065 (0.021) 2.0×10^{-06}	0.084 (0.031) 2.0×10^{-03}	0.079 (0.034) 1.2×10^{-02}
Exome chip (rare)	0.014 (0.019) 2.1×10^{-01}	0.040 (0.028) 7.7×10^{-02}	0.037 (0.029) 1.0×10^{-01}
Exome chip (common)	0.051 (0.011) 5.2×10^{-07}	0.044 (0.015) 1.3×10^{-03}	0.042 (0.017) 7.7×10^{-03}

Table S23. Components of heritability of Schizophrenia from exome chip. Estimates of h_g^2 are reported from variance components in the homogenous Swedish sub-population as well as all samples. Top panel shows estimates (without accounting for shared variance due to LD between classes) in All samples, homogenous Swedish sub-population, and LD-adjusted¹ estimates (h_{gLD}^2) from the homogenous Swedish sub-population. Bottom panel shows corresponding joint estimates accounting for shared variance due to LD. In bottom panel, P -values from a likelihood ratio test on the corresponding component are shown below each row.

A: GWAS chip + Exome chip						
Annotation	h_g^2 (se)	% h_g^2 (se)	% Non-coding SNPs	Enrichment (se)	P -value	
Coding (common)	0.049 (0.015)	NA	NA	NA	NA	
Coding (rare)	0.037 (0.028)	NA	NA	NA	NA	
UTR	0.003 (0.007)	1.1% (2.4%)	1.9%	0.59 (1.24)	7.4e-01	
Promoter	0.006 (0.008)	2.2% (3.0%)	3.0%	0.73 (1.00)	7.8e-01	
DHS	0.114 (0.023)	41.2% (8.0%)	25.7%	1.60 (0.31)	5.3e-02	
Intron	0.083 (0.019)	30.2% (6.4%)	26.2%	1.15 (0.25)	5.3e-01	
Intergenic	0.070 (0.023)	25.3% (7.4%)	43.2%	0.59 (0.17)	1.6e-02	
B: GWAS chip						
Annotation	h_g^2 (se)	% h_g^2 (se)	% SNPs	Enrichment (se)	P -value	
Coding	0.014 (0.007)	4.3% (2.3%)	2.0%	2.15 (1.13)	3.1e-01	
UTR	0.005 (0.007)	1.6% (2.1%)	1.9%	0.84 (1.12)	8.9e-01	
Promoter	0.009 (0.008)	2.8% (2.6%)	2.9%	0.95 (0.90)	9.5e-01	
DHS	0.118 (0.023)	37.8% (7.1%)	25.2%	1.50 (0.28)	7.3e-02	
Intron	0.092 (0.019)	29.5% (5.8%)	25.7%	1.15 (0.22)	5.1e-01	
Intergenic	0.075 (0.023)	24.0% (6.6%)	42.4%	0.57 (0.16)	5.7e-03	
C: 1000G imputed + Exome chip						
Annotation	h_g^2 (se)	% h_g^2 (se)	% Non-coding SNPs	Enrichment (se)	P -value	
Coding (common)	0.050 (0.016)	NA	NA	NA	NA	
Coding (rare)	0.035 (0.028)	NA	NA	NA	NA	
UTR	0.030 (0.016)	11.0% (5.9%)	0.8%	13.26 (7.08)	8.3e-02	
Promoter	-0.017 (0.019)	-6.1% (7.0%)	2.3%	-2.63 (2.99)	2.3e-01	
DHS	0.144 (0.059)	53.0% (20.4%)	16.9%	3.13 (1.21)	7.7e-02	
Intron	0.044 (0.032)	16.0% (11.8%)	28.7%	0.56 (0.41)	2.8e-01	
Intergenic	0.071 (0.035)	26.1% (12.6%)	51.2%	0.51 (0.25)	4.7e-02	
D: 1000G imputed						
Annotation	h_g^2 (se)	% h_g^2 (se)	% SNPs	Enrichment (se)	P -value	
Coding	0.056 (0.014)	17.6% (4.8%)	0.4%	45.89 (12.43)	3.1e-04	
UTR	0.023 (0.015)	7.2% (4.7%)	0.8%	8.66 (5.68)	1.8e-01	
Promoter	-0.024 (0.018)	-7.7% (5.7%)	2.3%	-3.31 (2.47)	8.2e-02	
DHS	0.169 (0.055)	53.6% (16.4%)	16.9%	3.18 (0.97)	2.5e-02	
Intron	0.025 (0.030)	7.8% (9.5%)	28.6%	0.27 (0.33)	2.8e-02	
Intergenic	0.068 (0.032)	21.6% (10.1%)	51.0%	0.42 (0.20)	3.7e-03	

Table S24. Components of heritability from regulatory elements in SWE-SCZ schizophrenia. Estimates are reported from the homogenous Swedish sub-population.

Coding f_{\max}	Homogenous	All
Singleton	0.000 (0.007)	0.000 (0.004)
0.001	0.000 (0.009)	0.000 (0.006)
0.005	0.000 (0.010)	0.004 (0.007)
0.010	0.000 (0.011)	0.006 (0.008)
0.050	0.025 (0.013)	0.031 (0.009)

Table S25. Collapsed-variant \hat{h}_g^2 of Schizophrenia from exome chip. For a given cohort, the variance of the heritability estimate tends to grow with the number of markers analyzed. Borrowing from gene-based burden association tests^{7,8}, we considered a strategy for reducing the variance of this estimate by collapsing rare variants in a gene into a single polymorphic site when computing the GRM. Over the full data-set, this procedure collapses the 60,000 effective SNPs into approximately 16,000 genes that contain polymorphic SNPs. This technique also has the benefit of incorporating singleton variants that violate the traditional variance-components model normality assumptions. However, as with burden-tests, the model assumes that all SNPs have identical normalized effect-sizes and will exhibit downwards bias when this assumption is violated. Formally, the method recodes each gene as a multi-allelic “pseudo-SNP” where samples that carry a minor allele below frequency threshold f_{\max} are considered carriers of the pseudo-SNP allele equal to the number of such variants they carry. The pseudo-SNPs are then normalized to have mean=0 and variance=1 and a new GRM is computed over the normalized pseudo-SNPs as in the standard model. The corresponding measure of $h_{g,\text{collapsed}}^2$ is estimated from this collapsed variance-component, jointly with a single non-coding component, which fully accounts for the minimal tagging of h_g^2 from non-coding regions by collapsed variants (Table S41). Our simulations show that disease architectures with > 50% non-causal (or non-deleterious) variants capture substantially less heritability as to make this approach underpowered compared to the standard model considering all SNPs (Table S42, S43). This table reports estimates of heritability from gene-based collapsed variants computed in two sub-groups of Swedish samples with increasing allele frequency thresholds. Analytical standard error reported in parenthesis.

Phenotype	Study	# SNPs	# Samples
RA	Stahl et al. 2010	2,556,272	25,708
T2D	Morris et al. 2012	2,473,442	149,821
CAD	Schunkert et al. 2011	2,420,361	22,233
SCZ	PGC2 2014	9,444,246	150,064

Table S26. GWAS summary statistics used for fine-mapping.

Sample size	# SNPs in critical set			P(causal in critical set)		
	No prior ¹	True prior ²	Wrong prior ³	No prior ¹	True prior ²	Wrong prior ³
4414	1132	309	310	0.95	0.94	0.84
8828	1024	279	280	0.97	0.96	0.87
13242	903	246	245	0.98	0.97	0.88
17656	747	202	201	0.98	0.97	0.89
22070	603	161	163	0.98	0.96	0.88
26484	485	128	125	0.97	0.96	0.88
30898	375	97	95	0.96	0.96	0.87
35312	276	70	72	0.96	0.94	0.86
39726	199	50	52	0.96	0.94	0.85
44140	145	38	39	0.95	0.93	0.83

For (Coding, UTR, Promoter, DHS, Intron, Intergenic) respectively the following models and priors were used:

¹Trait = (13.8 , 8.4 , 2.8 , 5.1 , 0.05 , 0.001); prior = (1.0 , 1.0 , 1.0 , 1.0 , 1.0 , 1.0)

²Trait = prior = (13.8 , 8.4 , 2.8 , 5.1 , 0.05 , 0.001)

³Trait = (6.6 , 3.3 , 0.5 , 4.3 , 0.3 , 0.1); prior = (13.8 , 8.4 , 2.8 , 5.1 , 0.05 , 0.001)

Table S27. Simulated fine-mapping analyses and calibration. Loci harboring a single typed causal variant were simulated from imputed SNPs and evaluated for fine-mapping over increasing sample sizes. The 95% critical set of causal variants was then computed with and without SNP priors, with set size and fraction of instances where the causal variant is in the critical set reported. “No prior” corresponds to a generative model where enrichment matches mean estimate from imputed data in main text and no prior is used for fine-mapping. “True prior” corresponds to the same generative model and the true enrichment is used as prior for fine-mapping. “Wrong prior” corresponds to the same fine-mapping priors but true enrichment set to the boundary of the confidence interval reported in main text. Each value is the mean from 2,000 simulations.

Component	Univariate R^2	Step-wise R^2	Step-wise PV	Multivariate PV
DHS	0.055	0.055	4.24e-104	7.49e-12
Intron	0.034	0.056	1.60e-03	2.83e-04
Intergenic	0.031	0.059	8.50e-07	6.22e-07
UTR	0.021	0.062	1.05e-07	7.34e-07
Promoter	0.016	0.062	3.46e-01	2.42e-01
Coding	0.009	0.062	2.24e-01	2.24e-01

We computed the expected GBLUP prediction accuracy using the previously derived^{9,10} relationship that M effective SNPs, N training samples, and h_g^2 are expected to yield prediction $r^2 = (h_g^2 h_g^2)/(h_g^2 + M/N)$. We did not account for ascertainment because prediction was assessed by cross-validation. For the PGC analysis, the observed-scale $h_g^2 = 0.49$, $N = 10000$ and we assumed $M = 60000$, which is expected to yield genome-wide $r^2 = 0.037$. Assuming independent variance components, we similarly estimated expected r^2 of the functionally stratified predictor by evaluating (jointly estimated) component-specific h_g^2 directly in the data, estimating M from the fraction of SNPs in each component, and summing all of the functional expected r^2 to compute the genome-wide prediction. For the PGC analysis, this yielded an expected genome-wide $r^2 = 0.077$, or a $2.08\times$ increase over the standard predictor.

Table S28. BLUP prediction accuracy in PGC. The h_g^2 for a set of SNPs is an upper-bound on the prediction accuracy of a polygenic score constructed from those SNPs in unrelated samples⁹⁻¹¹. To evaluate the impact of functional partitioning on risk prediction, we compared GBLUP^{12,13} prediction accuracy using six jointly estimated functional components vs. a single genome-wide component in the phase 1 subset of the PGC schizophrenia data (11,000 samples, see Materials and Methods). BLUP coefficients were computed in GCTA¹⁴ (see Web Resources) using the imputed data in a model with a single genome-wide component and a separate model with the six functional category components and converted into SNP effects. Risk scores were then computed from the SNPs and effects in each component. We assessed prediction accuracy using 10-fold cross-validation, where component-specific heritability and BLUP values were only estimated in the $\sim 10,000$ training samples. To account for population structure we included 10 principal components as fixed-effects in training the BLUP. We also included the same number of PCs when evaluating the predicted phenotype in a logistic regression with the true phenotype, reporting the Nagelkerke pseudo- R^2 of each model minus that of the principal components. Results are reported in Table S28. In this table, prediction R^2 and significance is reported for GBLUPs estimated from six functional categories jointly in 10-fold cross-validation. Univariate R^2 column reports the accuracy of a 1-dof predictor from each of the component individually. Step-wise R^2 column reports the accuracy of a multiple-dof prediction with each component added as an additional predictor in turn. Step-wise PV column reports P -value from the newly added predictor. Multivariate PV reports P -value from each predictor in the final 6-dof prediction model. In all instances, principal components were included as additional fixed-effects and subtracted from prediction R^2 . Of the six jointly estimated components, DHS yielded the highest individual R^2 (0.055) and coding yielded the lowest (0.009). A single degree of freedom GBLUP prediction from the sum of all six components yielded a highly significant R^2 of 0.061 ($P < 10^{-20}$). However, GBLUP prediction using a single component was only slightly less accurate, with $R^2 = 0.058$ ($P = 2.6 \times 10^{-7}$ for difference). On the observed-scale OLS R^2 , this corresponds to a genome-wide $r^2 = 0.043$ and a stratified $r^2 = 0.046$. Though highly statistically significant, the observed-scale increase of $1.07\times$ is substantially lower than the $2.08\times$ that would be expected in the case of independent markers (see Footnote). This indicates that the assumption of component independence is strongly violated and significant enrichments in component h_g^2 do not necessarily translate into increased prediction accuracy.

Genotyped:						
Category	causal MAF < 0.50		causal MAF < 0.05		causal MAF _{DHS} < 0.05	
	empirical sd	REML se	empirical sd	REML se	empirical sd	REML se
Coding	0.009	0.008	0.011	0.010	0.011	0.010
UTR	0.009	0.009	0.011	0.011	0.011	0.011
Promoter	0.015	0.015	0.017	0.016	0.016	0.016
DHS	0.059	0.053	0.050	0.051	0.051	0.051
Intron	0.047	0.047	0.041	0.042	0.042	0.042
Intergenic	0.058	0.058	0.050	0.050	0.051	0.050
Imputed:						
Category	causal MAF < 0.50		causal MAF < 0.05		causal MAF _{DHS} < 0.05	
	empirical sd	REML se	empirical sd	REML se	empirical sd	REML se
Coding	0.033	0.032	0.033	0.032	0.032	0.032
UTR	0.033	0.033	0.033	0.033	0.032	0.033
Promoter	0.042	0.041	0.042	0.041	0.044	0.041
DHS	0.124	0.124	0.125	0.124	0.126	0.124
Intron	0.069	0.068	0.069	0.068	0.067	0.069
Intergenic	0.077	0.075	0.073	0.075	0.077	0.075

Table S29. Empirical and analytical standard error of partitioned h_g^2 . Over 1,000 simulations for each of three disease architectures, the empirical standard deviation and average REML analytical standard error is reported for each functional category.

Phenotype	Coding	DHS	Promoter	UTR	Intron	Intergenic
SP (REML)	0.020 (0.029)	0.376 (0.133)	0.074 (0.044)	0.025 (0.031)	0.266 (0.094)	0.239 (0.106)
SP (jknife)	0.024 (0.027)	0.368 (0.168)	0.085 (0.047)	0.022 (0.019)	0.258 (0.143)	0.244 (0.088)
AS (REML)	0.069 (0.048)	0.418 (0.161)	0.052 (0.057)	0.114 (0.046)	0.149 (0.117)	0.198 (0.127)
AS (jknife)	0.086 (0.048)	0.419 (0.188)	0.040 (0.057)	0.102 (0.052)	0.115 (0.149)	0.238 (0.112)
MS (REML)	0.064 (0.017)	0.331 (0.053)	0.061 (0.020)	0.039 (0.014)	0.242 (0.040)	0.264 (0.042)
MS (jknife)	0.073 (0.023)	0.339 (0.076)	0.050 (0.021)	0.046 (0.012)	0.235 (0.034)	0.258 (0.068)
UC (REML)	0.047 (0.025)	0.433 (0.109)	0.087 (0.037)	0.043 (0.026)	0.212 (0.076)	0.179 (0.086)
UC (jknife)	0.045 (0.027)	0.425 (0.105)	0.085 (0.039)	0.045 (0.028)	0.223 (0.069)	0.177 (0.077)
BD (REML)	0.035 (0.024)	0.340 (0.103)	-0.010 (0.033)	0.036 (0.025)	0.229 (0.080)	0.370 (0.089)
BD (jknife)	0.030 (0.027)	0.321 (0.129)	-0.021 (0.035)	0.047 (0.022)	0.245 (0.088)	0.377 (0.093)
CAD (REML)	0.017 (0.032)	0.411 (0.154)	0.045 (0.052)	0.056 (0.037)	0.245 (0.120)	0.226 (0.138)
CAD (jknife)	0.018 (0.025)	0.432 (0.137)	0.048 (0.054)	0.058 (0.039)	0.225 (0.105)	0.220 (0.134)
CD (REML)	0.037 (0.025)	0.584 (0.119)	0.073 (0.040)	-0.008 (0.025)	0.149 (0.088)	0.165 (0.103)
CD (jknife)	0.036 (0.025)	0.619 (0.113)	0.071 (0.050)	0.005 (0.029)	0.134 (0.107)	0.133 (0.117)
HT (REML)	0.062 (0.029)	0.283 (0.117)	0.049 (0.042)	0.055 (0.030)	0.194 (0.094)	0.356 (0.105)
HT (jknife)	0.062 (0.027)	0.319 (0.110)	0.058 (0.052)	0.057 (0.026)	0.210 (0.083)	0.293 (0.116)
RA (REML)	-0.006 (0.049)	0.464 (0.234)	0.019 (0.076)	0.071 (0.057)	0.065 (0.189)	0.388 (0.201)
RA (jknife)	-0.017 (0.037)	0.444 (0.325)	-0.007 (0.085)	0.069 (0.063)	0.063 (0.193)	0.443 (0.241)
T1D (REML)	0.079 (0.046)	0.282 (0.180)	0.110 (0.067)	0.051 (0.044)	0.367 (0.147)	0.112 (0.171)
T1D (jknife)	0.077 (0.050)	0.301 (0.158)	0.114 (0.076)	0.061 (0.054)	0.361 (0.103)	0.088 (0.161)
T2D (REML)	-0.020 (0.030)	0.694 (0.160)	-0.035 (0.047)	-0.007 (0.032)	0.261 (0.114)	0.107 (0.136)
T2D (jknife)	-0.020 (0.041)	0.769 (0.146)	-0.030 (0.048)	-0.019 (0.040)	0.208 (0.160)	0.096 (0.180)
meta (REML)	0.040 (0.008)	0.384 (0.033)	0.050 (0.012)	0.035 (0.008)	0.226 (0.025)	0.250 (0.028)
	2.59e-04	7.98e-06	1.94e-02	2.21e-03	6.40e-02	4.11e-13
meta (jknife)	0.039 (0.009)	0.418 (0.038)	0.043 (0.013)	0.040 (0.008)	0.228 (0.024)	0.238 (0.032)
	1.10e-03	1.50e-06	1.07e-01	6.45e-05	6.72e-02	1.78e-11

Table S30. Comparison of analytical and jack-knife % h_g^2 from genotyped SNPs. For each trait and functional category, the % h_g^2 and standard error (in parentheses) is shown from a the standard REML and a weighted block-jackknife dropping each chromosome in turn. Results from meta-analysis for each method shown at the bottom, with P -values for enrichment below each entry.

Phenotype	Coding	DHS	Promoter	UTR	Intron	Intergenic
BD (REML)	0.049 (0.072)	0.346 (0.265)	-0.110 (0.093)	0.116 (0.076)	0.270 (0.153)	0.330 (0.162)
BD (jknife)	0.029 (0.079)	0.244 (0.294)	-0.110 (0.119)	0.155 (0.086)	0.338 (0.173)	0.345 (0.172)
CAD (REML)	0.075 (0.125)	0.007 (0.468)	0.028 (0.160)	0.105 (0.130)	0.444 (0.275)	0.341 (0.272)
CAD (jknife)	0.052 (0.113)	0.058 (0.598)	0.024 (0.163)	0.125 (0.103)	0.449 (0.352)	0.301 (0.307)
CD (REML)	0.192 (0.082)	1.517 (0.271)	-0.036 (0.095)	0.031 (0.076)	-0.309 (0.156)	-0.395 (0.173)
CD (jknife)	0.201 (0.090)	1.506 (0.367)	-0.042 (0.106)	0.044 (0.088)	-0.289 (0.196)	-0.417 (0.176)
HT (REML)	0.255 (0.105)	0.938 (0.316)	-0.030 (0.118)	0.127 (0.095)	-0.324 (0.186)	0.034 (0.198)
HT (jknife)	0.253 (0.096)	0.902 (0.431)	-0.020 (0.181)	0.122 (0.086)	-0.266 (0.169)	0.008 (0.261)
RA (REML)	0.014 (0.176)	1.627 (0.674)	0.283 (0.246)	0.212 (0.193)	-0.789 (0.451)	-0.346 (0.420)
RA (jknife)	0.026 (0.213)	1.592 (0.952)	0.285 (0.218)	0.250 (0.204)	-0.826 (0.347)	-0.340 (0.460)
T1D (REML)	0.350 (0.161)	1.062 (0.425)	0.288 (0.183)	-0.018 (0.129)	-0.083 (0.260)	-0.599 (0.308)
T1D (jknife)	0.370 (0.165)	0.992 (0.509)	0.290 (0.194)	0.004 (0.121)	-0.126 (0.314)	-0.528 (0.287)
T2D (REML)	0.025 (0.081)	0.638 (0.275)	-0.033 (0.102)	0.087 (0.085)	0.171 (0.174)	0.111 (0.172)
T2D (jknife)	0.022 (0.063)	0.668 (0.164)	-0.048 (0.064)	0.084 (0.094)	0.165 (0.186)	0.110 (0.095)
SP (REML)	0.077 (0.066)	0.443 (0.228)	-0.097 (0.077)	0.008 (0.063)	0.373 (0.140)	0.196 (0.141)
SP (jknife)	0.077 (0.067)	0.401 (0.186)	-0.063 (0.090)	0.007 (0.052)	0.373 (0.130)	0.206 (0.134)
MS (REML)	0.055 (0.029)	0.777 (0.094)	0.117 (0.040)	0.080 (0.031)	0.015 (0.057)	-0.045 (0.057)
MS (jknife)	0.058 (0.026)	0.782 (0.144)	0.115 (0.052)	0.089 (0.039)	0.002 (0.080)	-0.048 (0.071)
AS (REML)	0.015 (0.104)	1.063 (0.334)	0.075 (0.135)	0.209 (0.120)	-0.236 (0.206)	-0.126 (0.202)
AS (jknife)	0.019 (0.107)	1.065 (0.437)	0.073 (0.118)	0.193 (0.178)	-0.232 (0.265)	-0.120 (0.235)
UC (REML)	0.076 (0.059)	0.935 (0.194)	0.238 (0.079)	-0.014 (0.057)	-0.056 (0.115)	-0.180 (0.124)
UC (jknife)	0.079 (0.058)	0.897 (0.235)	0.250 (0.100)	-0.043 (0.052)	-0.023 (0.123)	-0.161 (0.157)
meta (REML)	0.075 (0.020)	0.795 (0.066)	0.062 (0.026)	0.066 (0.020)	0.015 (0.039)	-0.031 (0.040)
	4.74e-04	3.64e-22	1.25e-01	4.28e-03	5.48e-12	2.84e-42
meta (jknife)	0.073 (0.019)	0.710 (0.077)	0.047 (0.029)	0.057 (0.022)	0.028 (0.047)	-0.002 (0.043)
	3.35e-04	5.45e-13	3.98e-01	2.25e-02	4.17e-08	3.18e-33

Table S31. Comparison of analytical and jack-knife % h_g^2 from imputed SNPs. For each trait and functional category, the % h_g^2 and standard error (in parentheses) is shown from a the standard REML and a weighted block-jackknife dropping each chromosome in turn. Results from meta-analysis for each method shown at the bottom, with P -values for enrichment below each entry.

Phenotype	Prevalence	No fixed-effects		PCs as fixed-effects	
		REML (se)	Regression (se)	REML (se)	Regression (se)
BD	0.005	0.31 (0.033)	0.40 (0.034)	0.24 (0.035)	0.24 (0.035)
CAD	0.060	0.27 (0.061)	0.28 (0.059)	0.25 (0.062)	0.22 (0.059)
CD	0.001	0.18 (0.025)	0.22 (0.025)	0.17 (0.025)	0.20 (0.025)
HT	0.050	0.58 (0.097)	0.59 (0.093)	0.55 (0.098)	0.50 (0.093)
RA	0.005	0.10 (0.033)	0.11 (0.032)	0.09 (0.033)	0.08 (0.032)
T1D	0.005	0.14 (0.032)	0.15 (0.031)	0.13 (0.032)	0.13 (0.032)
T2D	0.080	0.50 (0.068)	0.62 (0.067)	0.42 (0.070)	0.43 (0.067)
SP	0.010	0.75 (0.013)	10.00 (0.021)	0.18 (0.024)	0.25 (0.055)
MS	0.001	0.29 (0.007)	2.91 (0.008)	0.17 (0.009)	0.21 (0.013)
AS	0.003	0.15 (0.027)	0.16 (0.026)	0.14 (0.027)	0.14 (0.026)
UC	0.001	0.15 (0.016)	0.15 (0.015)	0.14 (0.016)	0.14 (0.015)

Table S32. Total liability-scale h_g^2 from four inference methods. For each trait, the total estimate of h_g^2 is shown from the standard REML method and Haseman-Elston regression with and without included fixed-effects. Estimates were transformed to liability-scale using the given prevalence.

Phenotype	Prevalence	No fixed-effects		PCs as fixed-effects	
		REML	Regression	REML	Regression
BD	0.005	0.48 (0.20)	0.63 (0.14)	0.35 (0.27)	0.43 (0.24)
CAD	0.060	-0.08 (0.44)	-0.05 (0.39)	0.01 (0.47)	-0.10 (0.49)
CD	0.001	1.46 (0.26)	1.49 (0.21)	1.52 (0.27)	1.58 (0.24)
HT	0.050	0.91 (0.29)	1.06 (0.26)	0.94 (0.32)	1.12 (0.31)
RA	0.005	1.37 (0.57)	1.38 (0.52)	1.63 (0.67)	1.76 (0.75)
T1D	0.005	1.21 (0.40)	1.35 (0.36)	1.06 (0.43)	1.27 (0.43)
T2D	0.080	0.70 (0.24)	0.70 (0.18)	0.64 (0.28)	0.52 (0.26)
SP	0.010	0.56 (0.06)	0.75 (0.00)	0.44 (0.23)	0.09 (0.39)
MS	0.001	0.72 (0.06)	0.79 (0.00)	0.78 (0.09)	0.91 (0.11)
AS	0.003	1.09 (0.31)	1.09 (0.28)	1.06 (0.33)	1.07 (0.33)
UC	0.001	0.91 (0.18)	1.00 (0.16)	0.94 (0.19)	1.03 (0.18)

Table S33. Fraction of DHS h_g^2 from four inference methods. For each trait, the DHS estimate of % h_g^2 is shown from the standard REML method and Haseman-Elston regression with and without included fixed-effects.

Annotation	Regression % h_g^2	REML % h_g^2 (s.e.)
Coding	10%	8% (2%)
DHS	90%	79% (7%)
Promoter	5%	6% (3%)
UTR	8%	7% (2%)
Intron	-4%	2% (4%)
Intergenic	-9%	-3% (4%)

Table S34. Regression and variance-component estimates of functional enrichment. The meta-analyzed estimate of % h_g^2 is shown for analyses using regression and variance-components (REML). No shared-control adjustment was performed.

Category	% SNPs	polygenic % h_g^2 (se 100 trials)	DHS high-effect % h_g^2 (se 400 trials)
CODING	0.8%	0.7% (0.9%)	1.6% (0.4%)
UTR	1.1%	1.2% (0.9%)	0.7% (0.5%)
PROMOTER	2.8%	2.7% (1.1%)	3.5% (0.6%)
DHS	16.7%	15.6% (2.7%)	17.1% (1.8%)
INTRON	31.1%	30.2% (2.0%)	29.5% (1.1%)
OTHER	47.5%	49.6% (1.7%)	47.7% (1.1%)

Table S35. Partitioned h_g^2 with simulated case-control ascertainment. We simulated case-control ascertainment under two disease architectures and estimated % h_g^2 to assess ascertainment induced biases. Phenotypes were simulated on imputed chr1 SNPs (10% of genome) of the 33,000 sample combined WTCCC2 cohort, using 830 causal variants with no functional enrichment and $h_g^2 = 0.50$. “Polygenic” columns present results from simulation with randomly selected causal variants. “DHS high-effect” columns present results from simulation with only 16 causal DHS variants (each explaining 1% of the h_g^2), and 814 randomly selected non-DHS causal variants. Neither disease architecture lead to significant deviations from null enrichment. Ascertainment was induced by setting the top 1% of phenotypes to be cases (327 samples) and randomly selecting 654 non-cases to be controls, yielding a trait with 1% prevalence and 1:2 case:control ascertainment. Category-specific GRMs were then constructed for each ascertained cohort and h_g^2 was evaluated on the liability scale. Restricting to chromosome 1 resulted in an M/N equal to that of a $\sim 10,000$ sample cohort (where M is the effective number of SNPs, and N is the number of samples).

Category	polygenic	
	empirical sd	REML se
CODING	8.0%	7.1%
UTR	8.0%	8.4%
PROMOTER	10.5%	10.0%
DHS	25.1%	27.3%
INTRON	18.4%	16.3%
OTHER	15.7%	17.6%

Table S36. Empirical and analytical standard error of partitioned h_g^2 with case-control ascertainment. The empirical standard deviation and REML analytical standard-error shown for estimates of % h_g^2 for a simulated 1:2 case:control ascertained trait with prevalence of 1% (see Table S35 for simulation details). Under this quasi-polygenic architecture with 830 causal variants, the analytical SE is 0.2% higher on average. Estimates shown over 100 random simulations.

Joint GRM:	h_g^2 (se)
<u>known,non-coding</u> + non-coding	0.018 (0.004)
known,non-coding + <u>non-coding</u>	0.287 (0.028)
<u>known,coding</u> + known,non-coding + non-coding	0.006 (0.004)
known,coding + <u>known,non-coding</u> + non-coding	0.018 (0.004)
known,coding + known,non-coding + <u>non-coding</u>	0.286 (0.028)

Table S37. Components of heritability for known Schizophrenia loci. h_g^2 for multiple joint estimates at known schizophrenia loci are reported for the underlined component in the homogenous Swedish cohort.

Joint GRM	\hat{h}_g^2 (se)	\hat{h}_{gLD}^2 (se)
Common coding	10.7% (0.7%)	11.8% (0.9%)
Rare coding (non-singleton)	1.7% (1.6%)	0.7% (2.0%)
Joint GRM + non-coding	\hat{h}_g^2 (se)	\hat{h}_{gLD}^2 (se)
Common coding	-1.2% (0.7%)	-1.1% (0.9%)
Rare coding (non-singleton)	-0.6% (1.7%)	-2.3% (2.1%)

Table S38. Fraction of simulated common non-coding heritability inferred by coding variants.

Another potential source of confounding when estimating exome h_g^2 is heritability from nearby non-coding variants that is tagged by exonic variants due to LD. Because our interest is in identifying the purely exonic contribution to phenotype, we consider the heritability from these non-coding variants to “contaminate” our estimates. Using the GWAS chip data from this cohort allows us to quantify the amount of contamination expected due to common non-coding SNPs. We simulated a standard polygenic phenotype with $h^2 = 0.50$ coming exclusively from 5,000 randomly selected GWAS chip non-coding SNPs and then inferred h_g^2 using variance-components constructed from coding SNPs. No coding SNPs were used to generate the phenotypes, and if no contamination was present we expect the inferred h_g^2 to equal zero. Bottom panel shows results when a third variance-component corresponding to non-coding variants is estimated jointly in the model. Values reported represent the fraction of simulated heritability inferred averaged over 50 trials (with standard error in parenthesis). We found that all coding variants together accounted for an average of 17.4% of the non-coding heritability (Table S38), significantly different from zero. This further broke down to slight but non-significant contamination of 2.7% at rare coding variants ($\text{MAF} < 0.01$) and a highly significant average of 11.8% from common coding variants ($\text{MAF} \geq 0.01$), consistent with common variants being generally better tags of nearby common variation. Given the small physical size of the exome, contamination of 11.8% of the non-coding heritability could substantially bias the estimates from coding variants when estimated directly from exome chip data. To account for this contamination, we model an additional component consisting of the non-coding GWAS variants. When we conditioned in this way and estimate using a three variance-component model, we see statistically zero heritability attributed to the rare and common coding components. Because we only have genome-wide GWAS chip data available, which does not include rare variants and these variants are notoriously difficult to impute, the non-coding component is unlikely to account for contamination from rare non-coding variants. However, these variants would need to be physically close and in similar frequency to be strongly tagged by the rare coding variants we examined.

GRM genotypes	Causal variants	
	Rare coding	Common coding
non-coding	0.051 (0.012)	0.426 (0.006)
rare coding	0.509 (0.011)	0.043 (0.015)
common coding	0.024 (0.003)	0.514 (0.008)

Joint GRM genotypes	Causal Variants	
	Rare coding	Common coding
rare coding + non-coding	0.486 (0.003)	0.002 (0.001)
common coding + non-coding	0.025 (0.002)	0.485 (0.003)
rare coding + common coding	0.486 (0.004)	0.001 (0.001)
rare coding + common coding	0.000 (0.001)	0.482 (0.004)

Table S39. \hat{h}_g^2 of phenotypes simulated from coding variants. We set out to estimate the fraction of exome h^2 that is tagged by non-coding SNPs from the GWAS chip and 1,000 Genomes imputation. We simulate two groups of standard additive phenotypes from the rare and common exome variants, respectively, and infer $h_{g,\text{non-coding}}^2$ of these phenotypes from the non-coding SNPs. \hat{h}_g^2 inferred from different classes of GRMs is shown, with standard error over 10 trials in parenthesis. Lower panel shows results from multiple GRMs fit jointly, with bolded GRM corresponding to the reported variance-component estimate. The ratio of $\hat{h}_{g,\text{non-coding}}^2$ to simulated $h_{g,\text{exome}}^2$ gives us an estimate of the fraction of exome heritability tagged by non-coding variants. In 10 simulations from chromosome 22 with $h_{g,\text{exome}}^2 = 0.5$ the average ratio is 0.85 for common coding variants and 0.11 for rare coding variants (Table S39). However, the tagging between components is fully accounted for by a joint, three component model (Table S40).

Simulated h_g^2			Jointly inferred \hat{h}_g^2 (se)		
rare coding	common coding	all non-coding	rare coding	common coding	all non-coding
0.25	0.25	0.25	0.247 (0.003)	0.262 (0.002)	0.256 (0.003)

Table S40. Joint h_g^2 from simulated phenotype in Swedish schizophrenia cohort.

GRM	f_{\max}				
	Singleton	0.001	0.005	0.010	0.050
Collapsed	-0.009 (0.002)	-0.002 (0.002)	-0.002 (0.003)	-0.000 (0.003)	0.009 (0.004)
Collapsed + non-coding	-0.007 (0.002)	-0.004 (0.002)	-0.004 (0.003)	-0.004 (0.003)	0.001 (0.003)

Table S41. Collapsed \hat{h}_g^2 of phenotypes simulated from non-coding variants. An infinitesimal trait with $h_g^2 = 0.50$ was simulated from non-coding variants and \hat{h}_g^2 was inferred from coding variants collapsed below designated minor allele frequency f_{\max} . Mean and standard error are reported over 50 random trials. See Table S25 for method details.

f_{\max}	Effect distribution	Fraction causal			
		100%	50%	10%	1%
0.001	Uniform	0.49 (0.002)	0.33 (0.003)	0.21 (0.002)	0.17 (0.005)
0.001	Allelic	0.39 (0.003)	0.28 (0.003)	0.20 (0.003)	0.17 (0.007)
0.001	Normalized	0.33 (0.002)	0.22 (0.003)	0.16 (0.002)	0.16 (0.006)
0.005	Uniform	0.47 (0.002)	0.33 (0.005)	0.22 (0.002)	0.19 (0.006)
0.005	Allelic	0.37 (0.003)	0.28 (0.004)	0.21 (0.004)	0.18 (0.007)
0.005	Normalized	0.28 (0.003)	0.19 (0.004)	0.14 (0.002)	0.14 (0.006)
0.010	Uniform	0.47 (0.003)	0.34 (0.005)	0.24 (0.002)	0.20 (0.006)
0.010	Allelic	0.38 (0.002)	0.29 (0.006)	0.22 (0.003)	0.20 (0.007)
0.010	Normalized	0.24 (0.004)	0.17 (0.003)	0.13 (0.002)	0.15 (0.007)
0.050	Uniform	0.42 (0.003)	0.35 (0.006)	0.27 (0.003)	0.23 (0.008)
0.050	Allelic	0.35 (0.003)	0.30 (0.006)	0.28 (0.003)	0.23 (0.010)
0.050	Normalized	0.22 (0.003)	0.16 (0.005)	0.12 (0.002)	0.14 (0.006)

Table S42. Collapsed \hat{h}_g^2 of phenotypes simulated from rare coding variants. A quasi-infinitesimal trait was simulated from specified exome-wide causal fraction of coding variants and varying f_{\max} and total $h_g^2 = 0.5$. Effect-sizes were sampled from a standard normal distribution on the normalized-variant scale or the allelic-variant scale, and forced to be uni-directional within each gene. The collapsed \hat{h}_g^2 was then estimated from coding variants at the given f_{\max} . No more than half of the true h_g^2 can be recovered from collapsing under any disease architecture. See Table S25 for method details.

f_{\max}	Effect distribution	Fraction causal			
		100%	50%	10%	1%
0.001	Uniform	1.51	0.80	0.40	0.31
0.001	Allelic	1.00	0.63	0.38	0.31
0.001	Normalized	0.77	0.44	0.27	0.26
0.005	Uniform	1.54	0.92	0.49	0.42
0.005	Allelic	1.12	0.70	0.46	0.39
0.005	Normalized	0.72	0.41	0.24	0.26
0.010	Uniform	1.58	0.97	0.56	0.45
0.010	Allelic	1.14	0.76	0.51	0.46
0.010	Normalized	0.57	0.34	0.22	0.29
0.050	Uniform	1.31	0.96	0.72	0.59
0.050	Allelic	0.97	0.80	0.73	0.62
0.050	Normalized	0.48	0.31	0.20	0.26

Table S43. Power of collapsed vs. non-collapsed \hat{h}_g^2 for rare coding variants. The ratio of LRT statistics from collapsed / non-collapsed SNPs is reported for simulations with rare coding variants. Values < 1 indicate greater power for direct (rather than collapsed) estimates. See Table S25 for method details.

References

- [1] Gusev, A., Bhatia, G., Zaitlen, N., Vilhjalmsson, B., Diogo, D., Stahl, E., Gregersen, P., Worthington, J., Klareskog, L., Raychaudhuri, S., et al. (2013). Quantifying missing heritability at known gwas loci. *PLoS Genet* *9*, e1003993.
- [2] Schork, A. J., Thompson, W. K., Pham, P., Torkamani, A., Roddey, J. C., Sullivan, P. F., Kelsoe, J. R., O'Donovan, M. C., Furberg, H., Schork, N. J., et al. (2013). All snps are not created equal: Genome-wide association studies reveal a consistent pattern of enrichment among functionally annotated snps. *PLoS Genet* *9*, e1003449.
- [3] Pickrell, J. K. Joint analysis of functional genomic data and genome-wide association studies of 18 human traits. *The American Journal of Human Genetics* *94*, 559–573.
- [4] Pickrell, J. K. (2014). Are parameter estimates from fgwas unbiased?
- [5] Bulik-Sullivan, B., Loh, P.-R., Finucane, H., Ripke, S., Yang, J., Psychiatric Genomics Consortium, S. W. G., Patterson, N., Daly, M. J., Price, A. L., and Neale, B. M. (2014). Ld score regression distinguishes confounding from polygenicity in genome-wide association studies. *bioRxiv*.
- [6] Yang, J., Zaitlen, N., Goddard, M., Visscher, P., and Price, A. (2014). Advantages and pitfalls in the application of mixed-model association methods. *Nat Genet* *46*, 100–106.
- [7] Li, B. and Leal, S. M. (2008). Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data. *Am J Hum Genet* *83*, 311–321.
- [8] Price, A. L., Kryukov, G. V., de Bakker, P. I. W., Purcell, S. M., Staples, J., Wei, L.-J., and Sunyaev, S. R. (2010). Pooled association tests for rare variants in exon-resequencing studies. *Am J Hum Genet* *86*, 832–838.
- [9] Daetwyler, H. D., Villanueva, B., and Woolliams, J. A. (2008). Accuracy of predicting the genetic risk of disease using a genome-wide approach. *PLoS One* *3*, e3395.
- [10] Lee, S. H. and Wray, N. R. (2013). Novel genetic analysis for case-control genome-wide association studies: Quantification of power and genomic prediction accuracy. *PloS one* *8*, e71494.
- [11] Wray, N. R., Yang, J., Hayes, B. J., Price, A. L., Goddard, M. E., and Visscher, P. M. (2013). Pitfalls of predicting complex traits from snps. *Nat Rev Genet* *14*, 507–515.
- [12] Habier, D., Fernando, R. L., and Garrick, D. J. (2013). Genomic blup decoded: a look into the black box of genomic prediction. *Genetics* *194*, 597–607.
- [13] Speed, D. and Balding, D. J. (2014). Multiblup: improved snp-based prediction for complex traits. *Genome Res*.
- [14] Yang, J., Lee, S. H., Goddard, M. E., and Visscher, P. M. (2011). Gcta: a tool for genome-wide complex trait analysis. *Am J Hum Genet* *88*, 76–82.